Long-Acting Reversible Contraception: An Important Solution to Reduce Unintended Pregnancy
The content for this activity is based on the satellite symposium Long-Acting Reversible Contraception: An Important Solution to Reduce Unintended Pregnancy that was presented at The American Congress of Obstetricians and Gynecologists (ACOG) Annual District II Meeting in New York, New York, on October 22, 2016. Despite the availability of numerous contraceptive options, almost half of all pregnancies in the United States are unintended, creating a substantial negative health and socioeconomic burden on women and their families. The most commonly used contraceptives are dependent on adherence and “perfect use” to be efficacious, while long-acting reversible contraceptives (LARCs) offer the lowest failure rates primarily because they are user-independent. Greater use of the highly effective LARCs may provide one solution to the persistent problem of unplanned pregnancies and improve women’s and children’s health. This event was neither sponsored nor endorsed by ACOG.
This activity has been designed to meet the educational needs of health care professionals who provide care for women during their reproductive life.
Upon completion of this activity, participants will be better able to do the following:
- List and compare the benefits and limitations with regard to efficacy and safety of long-acting reversible contraceptives
- Describe the appropriateness of long-acting reversible contraceptives for women at risk for unintended pregnancy
- Employ a strong patient-provider collaborative approach to caring for sexually active female patients that includes patient education and shared decision-making regarding long-acting reversible contraceptives
Anita L. Nelson, MD (Program Chair)
Andrew M. Kaunitz, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
|Relationship Identified With:|
|Anita L. Nelson, MD|
Consultant/Advisor: Agile Therapeutics, Inc.; Allergan; Bayer AG; ContraMed LLC.; The Female Health Company; Merck & Co, Inc; Microchips Biotech, Inc.; PharmaNest
Speakers’ Bureau: Allergan; Aspen Pharmacare; Bayer AG; Merck & Co, Inc
Research/Grant Support: Agile Therapeutics, Inc.; Bayer AG; ContraMed LLC.; Merck & Co, Inc
|Andrew M. Kaunitz, MD|
Consultant/Advisor: Allergan; Bayer AG; Medicines360; Merck & Co, Inc; Pfizer Inc.
Research/Grant Support: Agile Therapeutics, Inc.; Bayer AG; Merck & Co, Inc
Royalties/Patents: UpToDate, Inc.
Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
This CME activity has been peer-reviewed by the American Journal of Obstetrics & Gynecology.
This activity has been supported by an independent educational grant from Teva Pharmaceuticals.
Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC, and Teva Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician